Cargando…

Longitudinal Neutralizing and Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants Following Messenger RNA Coronavirus Disease 2019 Vaccination

In this longitudinal prospective cohort of healthy adults in the United States, we found that coronavirus disease 2019 messenger RNA primary series and booster vaccinations elicited high titers of broadly cross-reactive neutralizing and antibody-dependent cell-mediated cytotoxicity antibodies, which...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xuemin, Ciric, Caroline, Gibson, Theda, Anderson, Larry J, Anderson, Evan J, Rostad, Christina A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10096895/ https://www.ncbi.nlm.nih.gov/pubmed/37065985 http://dx.doi.org/10.1093/ofid/ofad167

Ejemplares similares

Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection
por: Gaebler, Christian, et al.
Publicado: (2022)

Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine( )
por: Maron, Jenny S, et al.
Publicado: (2022)

Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals
por: Collier, Ai-ris Y, et al.
Publicado: (2021)

SARS-CoV-2 Antibody Profiles in Maternal Serum and Breast Milk Following mRNA COVID-19 Vaccination: A Longitudinal Prospective Observational Cohort Study
por: Hsiao, Hui-Mien, et al.
Publicado: (2023)

Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients
por: Muecksch, Frauke, et al.
Publicado: (2020)

The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein
por: Chen, Xuemin, et al.
Publicado: (2021)

Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer
por: Bloch, Evan M, et al.
Publicado: (2021)

Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera
por: Ha, Binh, et al.
Publicado: (2021)

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies
por: Wong, Serre-Yu, et al.
Publicado: (2021)

260. Durability of Antibody Responses to RSV in Older Adults Following Hospitalization for Acute Respiratory Infection
por: Ciric, Caroline, et al.
Publicado: (2023)

Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days
por: Haymond, Amanda, et al.
Publicado: (2021)

Decreased Risk of Coronavirus Disease 2019–Related Hospitalization Associated With the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2
por: Ridgway, Jessica P, et al.
Publicado: (2022)

Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
por: Agha, Mounzer E, et al.
Publicado: (2021)

Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents
por: Schauer, Jenna, et al.
Publicado: (2021)

Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019
por: Regan, James, et al.
Publicado: (2021)

Messenger RNA vaccines and neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Skin Adverse Reactions to Novel Messenger RNA Coronavirus Vaccination: A Case Series
por: Peigottu, Maria Francesca, et al.
Publicado: (2021)

Hyperinflammatory Syndromes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA vaccination in Individuals With Underlying Immune Dysregulation
por: Rocco, Joseph M, et al.
Publicado: (2021)

Severe acute respiratory syndrome coronavirus 2 antibody response to a third dose of homologous messenger RNA vaccination in liver transplantation recipients
por: Strauss, Alexandra T., et al.
Publicado: (2022)

Severe acute respiratory syndrome coronavirus-2 IgG antibody response to coronavirus disease 2019 vaccination in South Indian health-care professionals with and without coronavirus disease 2019 exposure
por: Jayashri, Ramamoorthy, et al.
Publicado: (2022)

Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2–Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients
por: Haidar, Ghady, et al.
Publicado: (2023)

Subgenomic RNA Abundance Relative to Total Viral RNA Among Severe Acute Respiratory Syndrome Coronavirus 2 Variants
por: Su, Maxwell, et al.
Publicado: (2022)

Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?
por: Anderson, Evan J, et al.
Publicado: (2020)

Coronavirus disease 2019 messenger RNA vaccine skin tests and serum histamine levels in allergic reactions
por: Kohli-Pamnani, Anita, et al.
Publicado: (2022)

Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis
por: Ammitzbøll, Christian, et al.
Publicado: (2021)

The Time Sequences of Respiratory and Rectal Viral Shedding in Patients With Coronavirus Disease 2019
por: Zhao, Fang, et al.
Publicado: (2020)

Clinical Sensitivity of Severe Acute Respiratory Syndrome Coronavirus 2 Nucleic Acid Amplification Tests for Diagnosing Coronavirus Disease 2019
por: Ridgway, Jessica P, et al.
Publicado: (2020)

Tropism of Severe Acute Respiratory Syndrome Coronavirus 2 for Barrett’s Esophagus May Increase Susceptibility to Developing Coronavirus Disease 2019
por: Jin, Ramon U., et al.
Publicado: (2021)

Potent Neutralizing Activity of Polyclonal Equine Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern
por: Luczkowiak, Joanna, et al.
Publicado: (2022)

Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Naive Nursing Home Residents
por: Canaday, David H, et al.
Publicado: (2021)

Croup during the Coronavirus Disease 2019 Omicron Variant Surge
por: Tunҫ, Emine M., et al.
Publicado: (2022)

Coronaviruses
por: Anderson, Larry J., et al.
Publicado: (2012)

Immature Platelet Fraction as a Biomarker for Disease Severity in Pediatric Respiratory Coronavirus Disease 2019
por: Lee, Nicholas C.J., et al.
Publicado: (2022)

Effect of Monoclonal Antibody Treatment on Clinical Outcomes in Ambulatory Patients With Coronavirus Disease 2019
por: Anderson, Blake, et al.
Publicado: (2021)

Awake Venovenous Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 Acute Respiratory Failure
por: Assanangkornchai, Nawaporn, et al.
Publicado: (2021)

1329. Burden of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF)
por: Salazar, Luis W, et al.
Publicado: (2021)

Risk of Symptomatic Infection During a Second Coronavirus Disease 2019 Wave in Severe Acute Respiratory Syndrome Coronavirus 2–Seropositive Individuals
por: Manica, Mattia, et al.
Publicado: (2021)

Fecal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) RNA Is Associated With Decreased Coronavirus Disease 2019 (COVID-19) Survival
por: Das Adhikari, Upasana, et al.
Publicado: (2021)

Coronavirus Disease 2019 Mitigation Strategies Were Associated With Decreases in Other Respiratory Virus Infections
por: Sinha, Pranay, et al.
Publicado: (2021)

Soluble Suppression of Tumorigenicity-2 Associates With Ventilator Dependence in Coronavirus Disease 2019 Respiratory Failure
por: Alladina, Jehan W., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5qlajd08la8213epi46u5em22u